Marees Tamara, Moll Annette C, Imhof Saskia M, de Boer Michiel R, Ringens Peter J, van Leeuwen Flora E
Department of Ophthalmology, VU University Medical Center, de Boelelaan 1117, 1007 MB Amsterdam, the Netherlands.
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9. doi: 10.1093/jnci/djn394. Epub 2008 Dec 9.
Survivors of hereditary retinoblastoma have an elevated risk of developing second malignancies, but data on the risk in middle-aged retinoblastoma survivors (ie, those with more than 40 years of follow-up) are scarce.
Data from the Dutch retinoblastoma registry were used to analyze risks of second malignancies in 668 retinoblastoma survivors, diagnosed from 1945 to 2005 (median age = 24.9 years) and classified as having had hereditary or nonhereditary disease based on the presence of family history, bilateral disease, or a germline RB1 mutation. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) of subsequent cancers in patients with hereditary and nonhereditary disease were estimated by comparison with Dutch sex-, age-, and calendar year-specific rates. Multivariable Cox regression and competing risk analyses were used to determine associations of treatment with risks of second malignancies. All statistical tests were two-sided.
After a median follow-up of 21.9 years, the risk of second malignancies in survivors of hereditary retinoblastoma (SIR = 20.4, 95% confidence interval [CI] = 15.6 to 26.1) far exceeded the risk of survivors of nonhereditary retinoblastoma (SIR = 1.86, 95% CI = 0.96 to 3.24). Among patients with hereditary disease, treatment with radiotherapy was associated with a further increase in the risk of a subsequent cancer (hazard ratio = 2.81, 95% CI = 1.28 to 6.19). After 30 years of follow-up, elevated risks of epithelial cancers (lung, bladder, and breast) were observed among survivors of hereditary retinoblastoma. After 40 years of follow-up, the AER of a second malignancy among survivors of hereditary retinoblastoma had increased to 26.1 excess cases per 1000 person-years. The cumulative incidence of any second malignancy 40 years after retinoblastoma diagnosis was 28.0% (95% CI = 21.0% to 35.0%) for patients with hereditary disease.
Our analysis of middle-aged hereditary retinoblastoma survivors suggests that these individuals have an excess risk of epithelial cancer. Lifelong follow-up studies are needed to evaluate the full spectrum of subsequent cancer risk in hereditary retinoblastoma survivors.
遗传性视网膜母细胞瘤幸存者发生第二原发恶性肿瘤的风险升高,但关于中年视网膜母细胞瘤幸存者(即随访时间超过40年者)风险的数据很少。
利用荷兰视网膜母细胞瘤登记处的数据,分析了668例视网膜母细胞瘤幸存者发生第二原发恶性肿瘤的风险,这些患者于1945年至2005年被诊断(中位年龄=24.9岁),并根据家族史、双侧疾病或种系RB1突变的存在情况分为遗传性或非遗传性疾病。通过与荷兰性别、年龄和历年特定发病率进行比较,估计遗传性和非遗传性疾病患者后续癌症的标准化发病比(SIRs)和绝对超额风险(AERs)。采用多变量Cox回归和竞争风险分析来确定治疗与第二原发恶性肿瘤风险之间的关联。所有统计检验均为双侧检验。
中位随访21.9年后,遗传性视网膜母细胞瘤幸存者发生第二原发恶性肿瘤的风险(SIR=20.4,95%置信区间[CI]=15.6至26.1)远远超过非遗传性视网膜母细胞瘤幸存者的风险(SIR=1.86,95%CI=0.96至3.24)。在患有遗传性疾病的患者中,放射治疗与后续癌症风险的进一步增加相关(风险比=2.81,95%CI=1.28至6.19)。随访30年后,在遗传性视网膜母细胞瘤幸存者中观察到上皮癌(肺癌、膀胱癌和乳腺癌)风险升高。随访40年后,遗传性视网膜母细胞瘤幸存者中第二原发恶性肿瘤的AER增加到每1000人年26.1例超额病例。对于患有遗传性疾病的患者,视网膜母细胞瘤诊断后40年任何第二原发恶性肿瘤的累积发病率为28.0%(95%CI=21.0%至35.0%)。
我们对中年遗传性视网膜母细胞瘤幸存者的分析表明,这些个体上皮癌风险过高。需要进行终身随访研究,以评估遗传性视网膜母细胞瘤幸存者后续癌症风险的全貌。